Corrigendum to “Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials”(European Urology, (2025), (S0302283825048778), 10.1016/j.eururo.2025.12.022)

The authors regret that, in the originally published version of this article, the following inconsistencies were identified. 1. The sentence: “Progression to muscle-invasive or metastatic disease was infrequent, with rates ranging from 3.1% in the CREST BCG induction + maintenance combination arm to 8.5% in the POTOMAC BCG-alone arm (Table 2).” has been corrected to: “Progression to muscle-invasive or metastatic disease was infrequent, with rates ranging from 1.4% in the CREST sasanlimab + BCG induction arm to 4.7% in the POTOMAC durvalumab + BCG induction + maintenance arm (Table 2).” 2. In Table 2, the proportion of patients with progression has been corrected to 15/340 (4.4%), instead of 15/340 (8.5%). 3. For consistency with the Supplementary Appendix, the heterogeneity metric reported in the text has been updated to include Cochran’s Q instead of I2, and now reads: Q = 1.08, p = 0.29. The authors would like to apologise for any inconvenience caused.